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Abstract
Background: HIV risk remains unacceptably high among adolescent girls and young women (AGYW) in southern
and eastern Africa, reflecting structural and social inequities that drive new infections. In 2015, PEPFAR (the United
States President’s Emergency Plan for AIDS Relief) with private-sector partners launched the DREAMS Partnership, an
ambitious package of interventions in 10 sub-Saharan African countries. DREAMS aims to reduce HIV incidence by
40% among AGYW over two years by addressing multiple causes of AGYW vulnerability. This protocol outlines an
impact evaluation of DREAMS in four settings.
Methods: To achieve an impact evaluation that is credible and timely, we describe a mix of methods that build on
longitudinal data available in existing surveillance sites prior to DREAMS roll-out. In three long-running surveillance
sites (in rural and urban Kenya and rural South Africa), the evaluation will measure: (1) population-level changes
over time in HIV incidence and socio-economic, behavioural and health outcomes among AGYW and young men
(before, during, after DREAMS); and (2) causal pathways linking uptake of DREAMS interventions to ‘mediators’ of
change such as empowerment, through to behavioural and health outcomes, using nested cohort studies with
samples of ~ 1000–1500 AGYW selected randomly from the general population and followed for two years. In
Zimbabwe, where DREAMS includes an offer of pre-exposure HIV prophylaxis (PrEP), cohorts of young women who
sell sex will be followed for two years to measure the impact of ‘DREAMS+PrEP’ on HIV incidence among young
women at highest risk of HIV. In all four settings, process evaluation and qualitative studies will monitor the delivery
and context of DREAMS implementation. The primary evaluation outcome is HIV incidence, and secondary
outcomes include indicators of sexual behavior change, and social and biological protection.
Discussion: DREAMS is, to date, the most ambitious effort to scale-up combinations or ‘packages’ of multi-sectoral
interventions for HIV prevention. Evidence of its effectiveness in reducing HIV incidence among AGYW, and
demonstrating which aspects of the lives of AGYW were changed, will offer valuable lessons for replication.
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Background
The incidence of HIV is declining or stabilizing in many
settings, yet levels of new infections remain unacceptably
high among adolescent girls and young women (AGYW)
[1]. In almost all countries with generalized epidemics,
young women aged 15–24 years are three to five times
more likely than their male counterparts to be living
with HIV; and in sub-Saharan Africa, 71% of new infec-
tions in adolescents are among girls [1]. In a pattern that
is consistent across most high prevalence countries, HIV
incidence rates rise dramatically between the ages of 15
and 24, and more steeply among females than males [2].
As the world’s population of adolescents grows, par-
ticularly in east and southern Africa, high incidence
among young people will equate to rises in the abso-
lute numbers of new infections [2, 3]. The role of
adolescent HIV prevention in broader epidemic con-
trol is recognized with the growing commitment at
global and national levels to prioritise young people
in efforts to end the AIDS epidemic. With the ‘All In
to End Adolescent AIDS’ campaign, for example,
UNICEF and global partners seek to reduce new HIV
infections among adolescents (10–19 years) by 75%
between 2015 and 2020, and ‘end’ the AIDS epidemic
among adolescents by 2030 (to fewer than 200 infec-
tions per year) [3]. The complexity of this goal is not
underestimated, and the multidimensional nature of
AGYW vulnerability has to date proven resistant to
change by single interventions, sectors or disciplines
[4]. The need for combination approaches, and ‘pack-
ages’ of interventions, is increasingly recognised. For
example, the recent issue of Disease Control Priorities
recommends an essential and cost-efficient ‘package’
to be delivered in adolescence – through a mixed ap-
proach involving the community, media and health
systems [5]. Similarly, a ‘call for action’ on HIV pre-
vention, ‘HIV Prevention 2020’, specifies a combin-
ation of primary prevention interventions, to be
designed comprehensively and delivered effectively
and at scale among populations at greatest risk [6].
The ‘DREAMS’ Partnership (http://www.dreamspartner-
ship.org/) is an ambitious programme aiming to halt
AGYW infections through such an approach: a broad
package of evidence-based health, educational and social
interventions to be delivered with urgency, high coverage,
and where the need is greatest. On World AIDS Day
2014, the United States President’s Emergency Plan
for AIDS Relief (PEPFAR), the Bill & Melinda Gates
Foundation and the Nike Foundation announced the
DREAMS investment in 10 countries in sub-Saharan
Africa [7]. The goal of DREAMS is to reduce new in-
fections by 40% after two years of intervention among
AGYW in sub-national geographic units identified as
‘hot-spots’ with high HIV burden.
By investing in a multi-component package, DREAMS
aims to address the root causes of girls’ and young
women’s vulnerability and improve their lives more
broadly – their value in society and their own esteem,
their experiences within relationships, opportunities for
schooling and employment, and healthy transitions from
adolescence to adulthood. The Partnership aims to en-
sure that AGYW have an opportunity to live Deter-
mined, Resilient, Empowered, AIDS-free, Mentored and
Safe lives (‘DREAMS’) in high-burden settings, through
interventions targeting young women, their families,
community and male sexual partners [7].
Evidence of DREAMS’ effectiveness can stimulate a
renewed focus on HIV prevention [6]. We sought the
best opportunities to independently evaluate the impact
of DREAMS in selected settings, in both general and key
population groups, to offer lessons to those implement-
ing DREAMS and to inform future investments in young
women’s health and well-being. To maximize the poten-
tial for generating evidence around DREAMS, four di-
verse settings in three countries – Kenya, Zimbabwe,
and South Africa – were chosen for this evaluation,
based on the availability of existing demographic and
HIV data platforms that would enable credible and
timely evaluation. The diversity of settings is an asset to
the generalisability of this evaluation, with each site pre-
senting distinct opportunities to generate evidence, but
it raises challenges in terms of ensuring comparability
and an appropriate level of harmonization across the dif-
ferent settings. This paper presents the overall protocol
for the evaluation in all four sites; details of the design
unique to the evaluation in Zimbabwe are published
elsewhere [8] and site-specific protocols for the other
three settings are available upon request.
The impact evaluation is funded independently of
DREAMS’ implementation and is a collaboration be-
tween the London School of Hygiene & Tropical Medi-
cine (LSHTM, UK); the Africa Health Research Institute
(AHRI) in KwaZulu-Natal, South Africa; the African
Population and Health Research Center (APHRC) in
Nairobi, Kenya; the Centre for Sexual Health and HIV
AIDS Research (CeSHHAR) in Zimbabwe; the Kenya
Medical Research Institute (KEMRI) in Kisumu, Kenya;
and the Liverpool School of Tropical Medicine (LSTM,
UK).
The DREAMS core package
The DREAMS Partnership supports a core package of
interventions targeted at AGYW, their families, wider
communities, and men characterized to be the sexual
partners of AGYW [7]. The package is comprised of
evidence-based interventions shown to address HIV risk
behaviours, HIV transmission, socio-economic vulner-
abilities and gender-based violence (Table 1).
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DREAMS investments aim to ensure that AGYW in
selected DREAMS areas (sub-national units with high
HIV burden) have access to all core package interven-
tions, either through DREAMS funding or additional
PEFPAR funding schemes (e.g., for VMMC) or coordin-
ation with national government programmes (e.g., for
cash transfers or educational subsidies). PrEP is
planned for selected countries and sites within coun-
tries, as determined by national governments. Guid-
ance for each component of the core package has
been provided to countries by PEPFAR, and coverage
targets have been set for each sub-national unit by
age group, area and intervention [9]. ‘Primary’ inter-
ventions are the priority interventions from the core
package that all AGYW in an age group should re-
ceive. ‘Secondary’ interventions are needs-based
interventions from the core package, recommended
for specific sub-populations of AGYW based on
additional circumstances, e.g., condom provision for
AGYW who are sexually active; post-violence care for those
who have experienced sexual violence. Additional file 1:
Table S1 summarises the primary and secondary interven-
tions in each country setting.
The way in which the various DREAMS components
are rolled out and coordinated, and the timing of imple-
mentation will differ in each evaluation site, depending
upon: the capacity and readiness of Implementing Part-
ners (IPs) contracted by the United States Government
to implement DREAMS services; the timing of contrac-
tual arrangements with IPs; negotiations with national
governments; finalization of sex education curricula for
schools; and other contextual factors. Given the hetero-
geneity in DREAMS’ delivery, we will monitor how,
when, by whom, and to whom, components of the
DREAMS package are delivered, in the process evalu-
ation activities described below [10].
Methods/Design
Aims & objectives
This protocol outlines the plans to evaluate the impact
of the DREAMS programme at the individual and
population levels in four sub-Saharan African settings
representing diverse epidemiological and social contexts.
The evaluation aims to answer three main questions:
1) What is the impact of the combined DREAMS
package on HIV infection rates and other key
outcomes, among AGYW and men who are in the
age range that includes most sexual partners of
AGYW?
2) Through what pathways do DREAMS interventions
affect the health, education, and social well-being of
individual AGYW?
3) What interventions were implemented and how
(with what timing, coverage and quality)?
In the South African and two Kenyan sites, the impact
of DREAMS, including community, facility, and
school-based interventions, on HIV infection rates and
other key outcomes will be measured in the general
population. In Zimbabwe, the impact of a combination
DREAMS package which includes an offer of oral PrEP,
alongside other interventions, on HIV infection rates
and other key outcomes will be evaluated among young
women who sell sex (YWSS) [8].
Theory of change
We hypothesize that DREAMS will reduce incidence of
HIV among AGYW through three related pathways of
protection (Fig. 1):
1) Social Protection: DREAMS will reduce social and
economic vulnerability of AGYW by helping them
Table 1 Interventions and target populations of the DREAMS Core Package
Target population and strategy Evidence-based intervention
Individual interventions (delivered directly to adolescent girls and young women)
Empower girls and young women and
reduce their risk
▪ Condom promotion and provision
▪ HIV testing and counselling services (HTS)
▪ Oral pre-exposure prophylaxis (PrEP) for HIV, offered to a subset of females at exceptionally
high risk and in select countries
▪ Post-violence care
▪ Expanded contraceptive method mix
▪ Social asset building
Contextual interventions (not all delivered directly to adolescent girls and young women but from which they can benefit)
Mobilize and strengthen the community
for change
▪ School-based HIV and violence prevention for boys and girls
▪ Community-based HIV and violence prevention for boys/young men and girls/young women
▪ Community mobilization and norms change for community leaders, boys and men
Strengthen families ▪ Parenting and caregiver programmes for vulnerable adolescent girls
▪ Social protection (cash transfers, educational subsidy, combination socioeconomic approaches)
Decrease risk in sexual partners of AGYW ▪ Characterisation of male partners to target highly effective interventions, e.g., HIV testing services,
antiretroviral therapy (ART) and voluntary medical male circumcision (VMMC)
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to stay in school; enabling financial independence to
offer socioeconomic alternatives to early marriage
and transactional sex; and reducing gender-based
violence and financial dependence on intimate
partners.
2) Sexual Behavior: DREAMS will reduce
acquisition of HIV by promoting safer sexual
behaviors and sexual networks among AGYW
and their male partners, including through
increased condom use.
3) Biological Protection: DREAMS will reduce the
likelihood of AGYW acquiring HIV through
biomedical technologies that lower the risk of
transmission of the virus (by reducing viral load
among HIV-positive male partners, through
increased knowledge of HIV status and uptake of
ART), and reducing the risk of acquisition of HIV
(PrEP, and VMMC for male partners).
Psycho-social mediators of change, such as empower-
ment and self-efficacy, are hypothesised to link uptake of
DREAMS interventions by AGYW to the three pathways
of protection and ultimately to a reduction of HIV inci-
dence among AGYW.
The impact of DREAMS interventions will depend on
the scale and intensity at which they are delivered and
whether they are accessed. Through the process evalu-
ation, we will assess the roles of supply of, demand for,
and adherence to, DREAMS interventions, as per the
conceptual framework for HIV prevention cascades [11].
More specifically, we will investigate the extent to which
interventions in the core package work in combination
to enhance the supply of prevention products/pro-
grammes, to limit barriers to access, and to create and
enhance opportunities and motivations for AGYW and
young men to adopt and adhere to them [10, 12].
Study settings
To maximize the potential for generating evidence on
the impact of the DREAMS Partnership, four settings in
three countries were chosen, each with existing demo-
graphic and/or HIV data platforms. In the South African
and two Kenyan sites, this evaluation will make use of
long-standing longitudinal health and demographic sur-
veillance systems (HDSS), while in Zimbabwe a national
programme to provide HIV-related services to sex
workers will serve as the evaluation’s starting point. The
HDSS provide direct measurement of trends in HIV
Fig. 1 Theory of change to guide the impact evaluation
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incidence as well as demographic, sexual behavior, and
linked clinical data to evaluate DREAMS’ impact. Data
from the national programme for sex workers in
Zimbabwe provide estimates of past HIV incidence and
a platform from which to identify and reach AGYW at
highest risk of HIV.
uMkhanyakude, KwaZulu-Natal, South Africa
The Africa Health Research Institute (AHRI; formerly
the Africa Centre for Population Health) in uMkhanya-
kude, KwaZulu-Natal, has followed a total of ~ 160,000
individuals from 11,000 geocoded households from
2000, in a 428 km2 surveillance area. Demographic sur-
veys have been conducted three times a year, with an-
nual collection of individual socio-economic, behavioral,
and HIV service uptake data alongside collection of
dried blood spots for laboratory testing for HIV infec-
tion. AHRI has a memorandum of understanding with
the Department of Health that enables linkage of the
population surveillance data to the primary care elec-
tronic record systems in the local health care facilities
(2010 onwards) and to the TIER.Net electronic record
system for HIV treatment (2004 onwards), as well as to
all clinical laboratory test results of patients in the
sub-district through linkage with the National Health
Laboratory Systems (NHLS) database (since 2004). Since
2017, AHRI has embedded clinical research assistants in
all primary health care settings in the surveillance area.
They electronically capture details on the reason for at-
tendance, and these clinic attendance data are linked to
the demographic surveillance data.
Gem sub-county, Siaya county, Kenya
The Kenya Medical Research Institute (KEMRI)/Centers
for Disease Control and Prevention (CDC) HDSS site in
Siaya County of western Kenya covers a total population
of approximately 223,000 people and 55,000 households,
with demographic surveys three times a year. Siaya
County includes three sub-counties: Rarieda, Siaya, and
Gem. For the evaluation of DREAMS, the KEMRI/CDC
platform in Gem will be used, as this is where HIV sur-
veillance has been conducted most frequently and re-
cently, i.e., three behavioral surveys and four rounds
offering HIV testing services in 2011/2012, 2013/14,
2016, and 2017, among a random sample of one-quarter
of all households and all resident members of those
households as an open cohort [13].
Nairobi county, Kenya
The African Population and Health Research Center
(APHRC) began the first urban-based longitudinal HDSS
platform in sub-Saharan Africa, known as the Nairobi
Urban Health and Demographic Surveillance System
(NUHDSS) in 2002 in two informal slum settlements of
Nairobi: Korogocho and Viwandani [14]. The NUHDSS
covers approximately 65,000 people and 24,000 house-
holds in 14 villages with quarterly sociodemographic
surveys and annual surveys (2012–2016) on fertility
preferences. As the last HIV serological survey was con-
ducted in 2007, HIV incidence will not be measured in
this setting. This site is conducting formative research
with 10–14 year olds for the Global Early Adolescent
Study (GEAS) [15], and will therefore be able to include
impact evaluation analyses from age 10 (unlike the other
3 evaluation settings which will focus on AGYW from
age 13).
Zimbabwe
The Zimbabwe evaluation will capitalise on a national
programme that provides HIV prevention and sexual
and reproductive health services to female sex workers
(FSW) in Zimbabwe, known as “Sisters with a Voice”.
‘Sisters’ began in 2009 and provides free access to HIV
testing, STI treatment, family planning, HIV prevention
education, condoms and legal services to over 65,000
women across 36 sites [16]. Around 40% of FSW acces-
sing the programme are younger than 25 years. The
evaluation will include six districts in which the Sisters
programme is active: two in which DREAMS+PrEP are
delivered (Bulawayo and Mutare) and four comparison
sites in which no DREAMS interventions are planned
(Karoi, Chinhoyi, Zvishavane and Kwekwe). Comparison
sites were selected for their comparability to interven-
tion sites in terms of population size, urban location,
and presence of a Sisters with a Voice site with relatively
high client volume [8].
Study design
The DREAMS package of interventions prioritises
AGYW, but also includes ‘contextual’ components di-
rected at young men, the families of AGYW, and the
wider community (Table 1). Consequently, the overall
impact of DREAMS interventions should be measured
at community, or “population”, level. For example, if
HIV incidence among AGYW is reduced following
DREAMS interventions then this is likely to have been
achieved through increased uptake of services and be-
haviour change among men as well as among AGYW
themselves.
In the evaluation settings in which impact is measured
in the general population (Nairobi, Gem, and Umkha-
nyakude), the primary way in which the impact of the
DREAMS programme will be measured is through com-
parisons of HIV incidence (Gem and Umkhanyakude
only), and HIV-related outcomes (in all 3 settings) across
calendar time periods before, during early roll-out, and
after DREAMS programmes have been established. This
has the disadvantage that changes over time may be due
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to factors other than DREAMS interventions, but the
advantage is that comparisons are made within the same
setting and population, at multiple time points. A
cluster-randomised trial design was not possible because the
priority of the DREAMS Partnership was for rapid roll-out
of DREAMS investments to geographic areas specifically
chosen for their relatively high HIV prevalence, rather than
to a randomly selected sample of areas [9].
For additional evidence of plausibility and impact,
changes in outcomes will be assessed by estimating
dose-response relationships between DREAMS uptake
and outcomes at the small-area level [17]. ‘Layering’ of
multiple interventions or services from the DREAMS
core package, through integration and referrals, will
be a key way of quantifying dose, for example, as the
percentage of AGYW who received multiple interven-
tion components and/or the minimum package de-
signed for their age.
In Zimbabwe, the main way in which impact will be
measured is through a comparison between 2 districts
which will receive DREAMS interventions with 4 dis-
tricts that will not. This alternative study design was
chosen because the study population is young women
who sell sex (not the general population of AGYW),
who are at high risk of HIV acquisition in all 6 study dis-
tricts, and a respondent-driven sample of YWSS will be
enrolled into a cohort study and followed up for two
years [8].
As well as measuring the overall impact of DREAMS
interventions at population-level, in the Kenyan and
South African settings a random sample of AGYW will
be enrolled into a “nested” (within the total population)
cohort study and followed up for two years, in order to
collect more detailed data on awareness and uptake of
interventions, psycho-social “mediators of change”, and
the three hypothesized pathways of change (social pro-
tection, sexual behaviour, and biological protection), and
thus enable in-depth analysis of pathways of change.
To achieve the above, the design comprises three main
components:
1) Population-based surveillance systems: In
uMkhanyakude, and Gem and Nairobi in Kenya,
existing surveillance systems that link HIV,
demographic, behavioural, and service uptake data,
will be used and enhanced in order to assess the
population-level effects of DREAMS over time (in
relation to the timing of DREAMS roll-out) among
AGYW, men who are in the age range that includes
most of the partners of AGYW, and also older
adults who may receive DREAMS interventions that
are directed at the wider community. In
uMkhanyakude and Gem, linkage to HIV clinic data
is possible and geospatial data are available, and in
uMkhanyakude HIV phylogenetics data are also
available. We will utilise historical (for baseline) and
prospective data (for comparison) from the
population-based systems (see Fig. 2 for example in
South Africa).
2) Cohorts of AGYW, randomly selected from the
total population: For detailed study of the pathways
by which DREAMS interventions influence HIV
Fig. 2 Timing and components (ongoing and new) of data collection embedded within a population platform: example of uMkhanyakude,
South Africa
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risk, we will establish cohorts of AGYW within
each evaluation site. Cohort enrolment will be
completed during the early roll-out of DREAMS
interventions, during 2017, and those enrolled will
be followed prospectively, at ~ 12 and ~ 24 months
later. There will be more detailed and comprehensive
data collection on uptake of DREAMS interventions,
mediators of change, and socio-economic,
behavioural and health outcomes than is possible in
the total population. In the Zimbabwe setting, the
same cohort used to measure the overall impact of
DREAMS interventions on HIV incidence among
YWSS can be used to analyse pathways of change.
In uMkhanyakude, Nairobi, and Gem, nested
cohorts of AGYW aged 13–22 will be selected
using the HDSS census population as the sampling
frame. A random sample of AGYW stratified by age
(13–17 and 18–22 years) and area of residence will
be selected. The Nairobi evaluation will further
recruit a sample of young girls from age 10
(building on the Global Early Adolescent Study
pilot in this setting), resulting in three age groups
for the cohorts: 10–14, 15–17, and 18–22 years.
In Zimbabwe, the network-based recruitment strategy
used to identify and refer YWSS to the DREAMS (inter-
vention sites) or Sisters (in comparison sites) programme,
is described in detail elsewhere [8]. This recruitment strat-
egy is appropriate in the absence of a sampling frame and
when the population of interest is primarily hidden as is
the case among young women who sell sex in Zimbabwe.
3) Process evaluation: In all four DREAMS
evaluation sites, a process evaluation will use
both qualitative and quantitative methods to
describe DREAMS implementation in context,
and to challenge and interrogate causal
assumptions in the theory of change [18]. To
understand DREAMS’ influence on supply,
demand, and uptake of interventions (the
‘prevention cascade’) [12], we will investigate
reach and coverage, views and experiences of
DREAMS components, what helps and hinders
successful implementation and uptake, and to
what extent implementation is influenced by
differing social and epidemiological contexts.
Specifically, we will explore fidelity (whether all
components of DREAMS were implemented on
schedule and as planned), feasibility (identifying
barriers and facilitators to implementation),
acceptability (how staff and beneficiaries perceive
and value the intervention), and quality (measured
by both objective and subjective criteria). In the
process, we will aim to identify unexpected
pathways and consequences, and who is left out
(equity).
The process evaluation will include five methodologies:
a. Qualitative longitudinal study of young people’s
experiences. Young people’s experience of and
“journeys” through DREAMS, including barriers
and facilitators to what works in practice will be
tracked in detail for a small cohort of 20 AGYW
and, in HDSS sites only, 20 young men in each site.
These cohorts – of DREAMS beneficiaries sampled
purposively from the general population (for males)
and AGYW cohorts (for females) – will be followed
longitudinally and offered a range of ways to share
their experiences in real-time including use of
diaries and informal interviews.
b. Small group discussions. The experiences of
AGYW’s families, parents, partners, and broader
communities will be explored through focus and
family group discussions. Group discussions in each
evaluation setting will help investigate
understanding and experience of DREAMS and its
components and whether social norms and
attitudes are influenced by the interventions.
c. Rapid participatory community mapping. This
method will be used in the DREAMS areas to
quickly gain a broad understanding of the social
context for adolescents and young people and the
reach and coverage of the AGYW services at
baseline and after two years of DREAMS
intervention. The mapping will use rapid appraisal
methods with participant observation and short
interviews.
d. Interviews with key informants in delivery
organizations. Up to 20 individuals responsible for
implementing DREAMS activities in each setting
will be interviewed to explore views and
experiences of, and barriers and facilitators to,
DREAMS activities each year. Local health care
workers and community and youth leaders will also
be interviewed.
e. Observations of DREAMS interventions delivered in
context. Using checklists, structured observations
will record the ways in which DREAMS is delivered
and received, and with what quality and intensity
(using DREAMS standard operating procedures for
reference). Observations will be made of DREAMS
interventions in a range of settings such as schools,
safe spaces, and health facilities.
Measurement and analysis of key variables
For component 1, the population-based surveillance in
the general population of AGYW and men, the primary
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comparison is across three time periods: pre-DREAMS,
during the early roll-out of DREAMS interventions, and
post-DREAMS. The aim is to know whether HIV inci-
dence among AGYW aged 15–24 years (the primary
outcome, directly observed through repeat testing) and
key secondary outcomes, measured among both AGYW
and men, have changed over time at population-level.
The primary and secondary outcomes are summarized
in Table 2, with secondary outcomes lying on the three
pathways of central interest that are between the inter-
ventions and HIV incidence: social, behavioural (sexual),
and biological protection. The extent to which any
changes can be attributed to DREAMS interventions will
be assessed in the context of other secular changes, and
the findings of the process evaluation. For example,
given the background scale-up of universal testing and
treatment for HIV, our findings on HIV incidence trends
among AGYW will be placed in the context of trends in
HIV incidence and the uptake of HIV testing and treat-
ment among those who are not directly targeted for
DREAMS HIV prevention interventions.
For component 2, the nested cohorts of AGYW de-
signed to measure pathways of change, the primary ex-
posure is uptake of DREAMS interventions among
individual AGYW, considering single components as
well as the number and combination of components of
the core package that were received. The extent to
which AGYW are aware of, invited into, and partici-
pate in DREAMS interventions will be summarized,
using the core package and primary/secondary inter-
ventions as frameworks to categorise interventions
and standardize across the settings. (See Table 3 for
proposed, a priori measures of DREAMS uptake.)
Comparisons of mediators and secondary outcomes
will then be made among AGYW according to their
uptake of DREAMS interventions.
‘Mediators of change’ (Fig. 1 and Table 3) will be mea-
sured at the individual level, representing the DREAMS
Partnership’s commitment that the interventions will in-
crease determination, resilience, empowerment, social
assets, and personal safety among AGYW.
Analysis plan
Analysis of primary outcome
In the South African and western Kenyan sites, we will
analyze population level change in directly-observed
HIV incidence over time, with all data available from the
Table 2 Primary and secondary measures of impact at the population-level in the South African and Kenyan evaluation sites, to be
estimated by comparing calendar time periods that represent pre-DREAMS, during early roll-out of DREAMS, and after DREAMS roll-out
Adolescent girls and young women Male sexual partners
15–19 years 20–24 years (15–34 years)
Primary Outcome HIV incidencea HIV incidencea
Secondary Outcomes
Biological protection Knows HIV statusb
HIV/STI prevalence STI prevalence & Incidence Uptake of VMMC
Use of ART
Community HIV viral loadd
Behavioral protection Ever had sex Number of sexual partners
(in last year / lifetime)
Age at first sex
Number of sexual partners (in last year / lifetime)
Age-disparity with sexual partners
Ever been pregnant Unmet need for contraceptionc Concurrency of sexual partners




Social protection In or completed school In employment or completed
vocational / microfinance training
Gender norms: support gender equity
Age at first marriage Experience of violence (exposure
to / victimization / perpetration)
Experience of violence
anot collected in Nairobi
bknow they are HIV+ or have tested HIV negative in the past 12 months
c do not want a child in next 2 years or ever but not using a method to prevent pregnancy
d uMkhanyakude only
e Used condom at last sex (in past 12 months); Any condomless sex in last 1 month / last 12 months and in the last 3 months
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Table 3 Outcomes, mediators of change in the outcomes, and uptake of DREAMS interventions, to be captured via nested DREAMS
cohorts of adolescent girls and young women (in Kenya and South Africa) and young women who sell sex (in Zimbabwe)
AGYW (South Africa and Kenya) YWSS (Zimbabwe)
13–17 yearsb 18–22 yearsb 18–24 years
Primary n/a a HIV incidence
Secondary Outcomes Knows HIV status
Number of lifetime
pregnancies
Reduced experience of violence
Incidence & prevalence of HSV-2/other STI HIV prevalence
Aware of partners’ HIV status Number of sexual partners
Engaged in transactional sex for
economic reasons
Age at first sex Number of sexual partners in
the last 12 months
Use of condoms & PrEP with regular/
transactional sex partners
Age at first /subsequent
pregnancies
Age at first / subsequent
pregnancies
Adherence to HIV treatment and
care services
Condom use Reduced food insecurity
Unmet need for contraception
Age-disparity with
sexual partners
HIV risk of sexual partners (to be
defined a priori)
No/less transactional sex
Stay in school In employment or completed
vocational / microfinance training
Age at first marriage or first long-term/live-in partner
Mediators of change
(Sample measures of constructs that
DREAMS aims to improve, specifically:
social assets, personal safety, self-
efficacy, common mental disorders,
empowerment, gender equitable
norms, and sexual relationship power)
Have at least one trusted female friend they can confide in Have at least one trusted female
friend they can confide in
Meet regularly in a safe place with peers Meet regularly at community
mobilization sessions with peers
and has increased sense of social
cohesion
Know a woman, other than mother/guardian,
to turn to if have a serious problem
Can access HIV prevention services
including condoms, STI treatment
& PrEP (as measure of self-efficacy)
and contraceptives
Is supported to adhere to PrEP, and
economically able to adhere/access PrEP
Able to avoid / refuse sex if sex is not wanted Has comprehensive knowledge of
HIV prevention
Able to refuse sex if partner will not use a condom
(or confident they can use a condom with all sex partners)
Have access to money in an emergency
Confident they could get a HIV test Is confident she can negotiate condom
use with sexual partners (including clients)
Confident they can access health services when they
need them (sexual and reproductive health services
in particular)
Able to avoid violent relationships
Have access to their own savings
Have access to money in an emergency
Believes a man and woman should decide together whether to
use a condom / what type of contraception to use
Birdthistle et al. BMC Public Health  (2018) 18:912 Page 9 of 15
HDSS sero-surveys, making comparisons among three
calendar time periods as follows:
 Pre-DREAMS roll-out: the 5–10 years prior to
DREAMS (up to and including 2015 in South Africa
and 2016 in Gem, Kenya [see ‘Sample Sizes’ below
for details])
 During early DREAMS implementation: 2016
 Post-DREAMS: 2017–2019 (rolled out)
Our main comparison will be between the post-DREAMS
time period, and the two earlier time periods.
In Zimbabwe, we will compare HIV incidence between
sites where DREAMS+PrEP has and has not been imple-
mented, over two years of follow-up. In the absence of
randomization, the analysis will adjust for known
individual-level determinants of HIV incidence.
Analysis of secondary outcomes
Secondary outcomes will be captured via the HDSS in
the three surveillance sites (Table 2) as well as via the
cohorts of young women in all four settings (Table 3).
We will analyze population and individual level change,
respectively, over time in these outcomes, using the cal-
endar time periods described above for HIV incidence.
Analysis of causal pathways
To explore whether the hypothesized “mediators of
change” lie on the causal pathway between the DREAMS
interventions and HIV-related (secondary) outcomes
(Table 2), longitudinal data collected from the nested
AGYW cohorts at three time points over two years will
be used (enrolment; 12 months; 24 months). The causal
analysis will involve four main steps:
1) Analysis of whether uptake of DREAMS
interventions is related to an improvement in the
“mediators of change”, between enrolment and
follow-up at 12 and 24 months
2) Analysis of whether uptake of DREAMS
interventions is related to “lower-risk” sexual
behaviour, social protections, and biological
protections, at follow-up at 12 and 24 months
3) Analysis of whether improved levels of the
“mediators of change” are related to “lower-risk”
sexual behavior, social protections, and biological
protections, at enrolment and during follow-up
4) Causal mediation analysis of the effect of DREAMS
interventions on secondary outcomes (biological,
behavioral, social), i.e., the extent to which any
effect of DREAMS interventions on secondary
outcomes after 12 and 24 months of follow-up is
achieved through their effect on the “mediating”
variables.
These analyses will adjust for important confounding
variables measured at enrolment (for example, house-
hold socio-economic position) and an AGYW’s “propen-
sity to receive” DREAMS interventions. This is because
the criteria used by DREAMS implementing partners to
select AGYW who will be invited to participate in the
programme are also likely to influence the outcomes
that are to be measured, i.e., they may be risk factors for
HIV incidence and the secondary outcomes, and so may
confound observed associations between uptake of inter-
ventions and these outcomes. For example, Implement-
ing Partners are prioritising girls considered to have the
highest risk of HIV infection (such as, those who are liv-
ing in relatively poor households, are orphans, are out of
school, or are young mothers, as identified via the ‘Girl
Table 3 Outcomes, mediators of change in the outcomes, and uptake of DREAMS interventions, to be captured via nested DREAMS
cohorts of adolescent girls and young women (in Kenya and South Africa) and young women who sell sex (in Zimbabwe)
(Continued)
AGYW (South Africa and Kenya) YWSS (Zimbabwe)
13–17 yearsb 18–22 yearsb 18–24 years
Uptake of DREAMS interventions • Invited to participate / enrolled in DREAMS
• Received at least one DREAMS intervention
• Received multiple intervention categories in
the DREAMS core package
• Received DREAMS primary or secondary
interventions (depending on age and need)
Intervention sites (versus comparison sites)
Within intervention sites, measures
of individual uptake will include:
• Received at least one DREAMS
intervention
• Received DREAMS package for key
populations (‘KP_Prev’c)
• Received KP_Prev + educational
subsidies or vocational training
• Received KP_Prev + PrEP
aIn South Africa and Gem, Kenya, HIV incidence will be estimated from the larger population-level studies (see Table 2), for adequate statistical power (see
‘Sample Sizes’ below)
b Age at enrolment, to be followed over two years
c‘KP_Prev’ is the PEPFAR indicator used to measure DREAMS package for key populations and includes condom promotion, HIV testing services, and social asset
building [22]
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Roster’ enumeration exercise and by community-based
organisations) [19]. The characteristics that predict ex-
posure to DREAMS will be identified using HDSS data,
and the information across these characteristics will be
synthesized into a single “propensity to be exposed to
DREAMS” score (equivalent to an estimated probability
of exposure to DREAMS, and taking values between 0
and 1), and AGYW will be categorized (stratified) into
4–5 groups on the basis of their propensity score. The
association between uptake of DREAMs interventions
and socio-economic and behavioural outcomes will be
adjusted for the propensity score (in categories) as well
as the individual characteristics that are the most im-
portant confounding variables.
Qualitative and process evaluation data
Analysis of the concurrent process evaluation data will
follow the UK Medical Research Council guidance for
process evaluation of complex interventions [18]. Data
collected using the range of different methods, detailed
above, will be carefully integrated to address the follow-
ing process evaluation questions:
 How is delivery of DREAMS achieved and what is
actually delivered? (Implementation)
 How does the delivered intervention produce
change? (Mechanisms of impact)
 How does context affect implementation and
outcomes? (Context)
The mechanisms to be scrutinised include increased
demand for (awareness and acceptability), supply of (ac-
cessibility and availability), and adherence to (ongoing
adoption) the interventions in the DREAMS core pack-
age, as per the HIV prevention cascade framework, to
achieve coverage among the target populations [11].
Sample sizes
HIV incidence - the primary endpoint for the impact
evaluation - will be measured using HDSS data in
uMkhanyakude and Gem, and data from the cohorts of
young women who sell sex in Zimbabwe. In uMkhanya-
kude, HIV incidence was ~ 6 per 100 person-years
among AGYW aged 15–24 years old during 2011–2015,
and ~ 4.6 and ~ 7.5 per 100 person-years among those
aged 15–19 and 20–24 years respectively, based on a
total of 7687 person-years of follow-up. Assuming, con-
servatively, that there will be ~ 3000 person-years of
follow-up during 2017–2019 (40% of 7687), [20] then
study power is > 90% to show an overall reduction in
HIV incidence of 30, and > 90% in sub-group analysis of
AGYW aged 15–19 and 20–24 years to show a 40% re-
duction in HIV incidence (Fig. 3a). In Gem, western
Kenya, HIV incidence was ~ 0.7 per 100 person-years
among AGYW aged 15–24 years during 2011–2016,
based on a total of 8236 person-years of follow-up [21].
(Whereas sero-surveys are conducted annually in
uMkhanyakude, they are less frequent in Gem: data are
available from three sero-surveys in Gem between 2011
and 2016. Sero-conversions observed during this period,
including those estimated from the 2016 survey, will be
considered ‘pre-DREAMS’ because they are unlikely to
be influenced by DREAMS by this early stage of imple-
mentation.) During 2017–2019, all AGYW in Gem will
be sought for participation in the HDSS; with a partici-
pation rate of 70% in each year, and an annual
out-migration rate of 20%, it is estimated that there will
be ~ 9000 person-years of follow-up during 2016–2019.
Study power is low to show a change in HIV incidence
in sub-group analyses of AGYW aged 15–19 and 20–
24 years, but ~ 80% to show an overall reduction of 45,
and 90% to show an overall reduction of 50% in HIV in-
cidence (Fig. 3b).
The same sample sizes will also allow us to detect
meaningful change in secondary outcomes that are more
common among AGYW than HIV incidence, includ-
ing knowledge of HIV status and use of condoms
(Additional file 1: Table S2). Secondary outcomes will
also be measured at the population level for men includ-
ing the proportion of males who know their HIV status,
uptake of voluntary male medical circumcision among
HIV-negative males, and uptake of anti-retroviral therapy
among HIV-positive males (Additional file 1: Table S3).
For the nested cohorts in the three HDSS sites, se-
lected from the HDSS sampling frames in South Africa
and Western Kenya, a minimum of 400 girls in each of
the 13–17 and 18–22 year age groups will allow us to
analyze causal relationships between key mediators and
key outcomes (Additional file 1: Table S4), and similarly to
analyze causal relationships between uptake of DREAMS
interventions and key outcomes. Over-sampling by 20%
will cater for non-response and loss-to-follow-up. In
Nairobi, for the additional cohort of 400 younger girls
aged 10–14), the sample size of 400 will allow us to ex-
plore pathways between uptake of DREAMS interven-
tions, key mediators and age-appropriate outcomes like
school completion.
In Zimbabwe, network-based recruitment will be used
to enroll 18 to 24-year-old women who sell sex from
intervention and comparison sites. Based on the as-
sumption that 20% of YWSS identified through this
process will test HIV-positive and 30% of HIV-negative
YWSS will be lost to follow-up over 24 months, it is esti-
mated that 1200 women from the intervention and com-
parison sites (2400 total) will be needed to detect a 40%
reduction in HIV incidence [8]. This sample size is also
sufficient to explore pathways linking DREAMS to sec-
ondary outcomes.
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Discussion
DREAMS is a direct response – probably the most ambi-
tious yet – to the call for combinations or ‘packages’ of
prevention approaches to address the multidimensional
nature of HIV risk. PEPFAR and its DREAMS partners
have set bold targets and allocated significant resources to
urgently reduce new HIV infections. It is important to learn
from these efforts, but evaluating such a multi-component
programme is complex.
In the first instance, a randomised design was not pos-
sible because DREAMS sites were not selected at random,
but chosen for their high burden of HIV prevalence and
incidence. Furthermore, interventions in the core package
cannot be rolled out at random, as implementation will
begin with the interventions already in place (e.g., through
pre-existing PEPFAR and national government pro-
grammes) and this is context-specific. Neither was a con-
trolled design possible, given the numerous differences
Fig. 3 Study power for comparing HIV incidence between post-DREAMS and pre-DREAMS time periods in (a) uMkhanyakude, South Africa and
(b) Gem, Kenya
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(non-comparability) across sub-national geographic units,
as well as the absence of existing surveillance/data plat-
forms in other areas, to allow for comparable data
collection.
We have proposed the most rigorous design feasible in
the absence of randomisation. Community-wide data
platforms allow us to evaluate DREAMS in large, general
populations, and provide the frameworks for randomly
selected, representative samples of young people for de-
tailed, nested studies. The range of data available (HIV,
demographic, social, spatial, clinical) can be linked to
maximize the range and depth of inquiry. In all settings,
detailed longitudinal data will allow us to investigate
pathways and explore change processes in the context of
DREAMS roll-out (and minimize recall and reporting
bias), and to account for a range of potential confound-
ing variables. Historical measures of HIV incidence and
other outcomes will provide baseline trend data, to help
distinguish the impact of DREAMS from existing trends
due to other factors.
In this study, estimates of HIV incidence will be dir-
ectly observed through repeat testing and can be com-
pared to levels of newly diagnosed infections in pregnant
women tested in antenatal clinics serving the study pop-
ulations, since the latter is a method by which PEPFAR
will assess programme impact in DREAMS sites (e.g.,
through monitoring of ante-natal care testing data as
part of Prevention of Mother to Child Transmission pro-
grammes) [22]. Tracking new HIV diagnoses can be a
helpful complement to incidence rates, offering insight
into the reach and yield of HIV testing services.
A particular challenge of this evaluation is also one of
its main strengths: harmonizing across diverse settings.
Each setting presents unique opportunities to deepen the
understanding of AGYW’s experience of DREAMS, but
coordinating the design and measures across settings is
not always possible. For example, in Nairobi, we have an
opportunity to understand DREAMS impact in an urban
setting and to capitalize on the site’s extensive experience
with young people, to track pathways through DREAMS
from a very young age. In this setting, however, we will
not be able to observe change in HIV incidence (except
indirectly, by monitoring antenatal clinic outcomes of
HIV testing). Gem offers a rural comparison to Nairobi,
where we can measure the added value of DREAMS fol-
lowing wide-scale roll-out of anti-retroviral therapy and
VMMC. In uMkhanyakude, we have an opportunity to
evaluate DREAMS in a setting where HIV risk has
remained persistently high and relatively few HIV preven-
tion interventions have targeted AGYW prior to
DREAMS. In Zimbabwe, no HDSS framework exists, but
we will gain insight into the DREAMS+PrEP package, and
understand HIV and HIV-related outcomes among an ex-
ceptionally vulnerable group of young women.
Working with existing research platforms offers infra-
structure, experience and data prior to DREAMS intro-
duction. However, it also means that data collection
cannot be conducted at the same time in each site, and
this must be taken into account in analyses and inter-
pretation. Also, community sensitisation efforts are
planned in each site to avoid research fatigue and
maximize data quality and validity in settings with fre-
quent and/or concurrent surveys. Furthermore, in each
setting, DREAMS is delivered through different models
of collaboration and implementation, and changes in im-
plementation will occur in each setting over time. This
heterogeneity and its influence on outcomes will need to
be understood through careful process evaluation.
With a portfolio of evaluations in diverse settings, the
sum can be greater than its parts. Learning within and
across sites, we can document the role of context and
adaptation in DREAMS impact, to inform replication in
a range of other diverse settings. The effectiveness of the
individual interventions in the DREAMS core package
have been demonstrated in previous trials and evalua-
tions. We now need to understand how they can be
combined for maximum reach, scale and impact. This
evaluation will investigate this in ‘real-world’, non-trial
conditions, providing immediately relevant and timely
lessons for future policy and programming.
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Additional file 1: Table S1. Summary of primary and secondary
packages of interventions in each country setting, by age where
applicable. Table S2. Estimated sample sizes to measure change over
time in secondary outcomes among AGYW. Table S3. Estimated sample
sizes to measure change over time in key outcomes among males.
Table S4. Estimated sample sizes to assess the causal effect of key
mediators of change on secondary outcomes (via cohorts of adolescent
girls and young women). (DOCX 58 kb)
Abbreviations
AGYW: Adolescent girls and young women; AHRI: Africa Health Research
Institute; APHRC: African Population and Health Research Center; ART:
Anti-retroviral therapy; CDC: United States Centers for Disease Control and
Prevention; CeSHHAR: Centre for Sexual Health and HIV AIDS Research;
DREAMS: Determined, Resilient, Empowered, AIDS-free, Mentored, Safe lives;
FGD: Focus group discussion; FSW: Female sex workers; GEAS: Global Early
Adolescent Study; HDSS: Health and demographic surveillance system;
HIV: Human immunodeficiency virus; HSV-2: Herpes simplex virus type 2;
HTC: HIV testing and counselling; HTS: HIV testing services; IE: Impact
Evaluation; IP: Implementing Partner for DREAMS; KEMRI: Kenya Medical
Research Institute; KP_Prev: Number of key populations reached with HIV
prevention interventions; KZN: KwaZulu-Natal; LSHTM: London School of
Hygiene & Tropical Medicine; LSTM : Liverpool School of Tropical Medicine;
NHLS: National Health Laboratory Services; PEP: Post-exposure prophylaxis
(for HIV); PEPFAR: The United States President’s Emergency Plan for AIDS
Relief; PrEP: Pre-exposure prophylaxis (for HIV); SRH: Sexual and reproductive
health; STI: Sexually transmitted infection; UK: United Kingdom; US: United
States; VMMC: Voluntary male medical circumcision; YWSS: Young women
who sell sex
Birdthistle et al. BMC Public Health  (2018) 18:912 Page 13 of 15
Acknowledgements
We are grateful to the following individuals for their helpful reviews of the
study proposal and for facilitating discussions with in-country DREAMS
organisers and implementers to finalise design details: Gina Dallabetta and
Geoff Garnett (BMGF); Janet Saul (CDC); Emily Gutierrez-Zielinski and Mary
Mwangi (CDC Kenya); Mary Glenshaw (CDC South Africa). We are indebted
to Despoina Xenikaki and Frankie Liew (LSHTM) for their skill and patience in
project and contract management, and the contributions by Justin Fenty
(formerly LSHTM) to sample size calculations and mapping of existing data.
The team at AHRI would like to thank Dickman Gareta, Tinofa Mutevedzi,
Kobus Herbst, Teresa Smit, Nuala McGrath, Frank Tanser and Till Barnighausen
for early support in protocol development. We are grateful to Basia Zaba for
facilitating collaborations for this research partnership, offering scientific
guidance for the design and analysis, and valuable comments on an early
draft of the manuscript.
Funding
The impact evaluation of DREAMS is funded by the Bill and Melinda Gates
Foundation (OPP1136774, http://www.gatesfoundation.org). Foundation staff
advised the study team, but did not substantively affect the study design,
instruments, interpretation of data, or decision to publish.
Availability of data and materials
Data underlying published results will be accessible and open, subject to a
transition period, as per the Open Access Policy of the Bill & Melinda Gates
Foundation.
Authors’ contributions
IB, SF and SS led the drafting of the manuscript. IB and SF are Principal
Investigators (PI) and responsible for overall conceptualization of study
design and analysis. MS, AZ, FMC, PPH and DK are Partner PIs and
responsible for design and implementation in uMkhanyakude, Nairobi,
Zimbabwe, and Gem, respectively. NC and TC contributed to design and will
provide study management. JRH and JRG serve as co-Investigators. AG
contributed to the overall analysis plan; CWK, KO and BH were involved in
study design in Nairobi, Gem, and Zimbabwe, respectively. All authors
reviewed a draft and read and approved the final manuscript.
Ethics approval and consent to participate
The study protocol, including informed consent and study tools, has been
reviewed and approved by the Observational Research Ethics Committee of
the London School of Hygiene and Tropical Medicine, and committees in
each of the host countries, specifically: KEMRI (Gem, Kenya); Amref Health
Africa in Kenya (Nairobi, Kenya); University of KwaZulu-Natal Biomedical
Research Ethics Committee (South Africa); and Medical Research Council of
Zimbabwe, and the Liverpool School of Tropical Medicine. Participants will
be asked for their informed, written consent to participate in all aspects of




The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Faculty of Epidemiology and Population Health, London School of Hygiene
& Tropical Medicine, Keppel Street, London WC1E 7HT, UK. 2University of
California at Santa Barbara, Santa Barbara, USA. 3Centre for Global Health
Research, Kenyan Medical Research Institute, Kisumu 40100, Kenya. 4Institute
for Global Health, University College of London, Capper St, London WC1E
6JB, UK. 5Africa Health Research Institute, 719 Umbilo Road, Durban,
KwaZulu-Natal 4001, South Africa. 6African Population and Health Research
Center, Manga Close off Kirawa Road, Nairobi, Kenya. 7Department of Clinical
Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool
L3 5QA, UK. 8Department of International Public Health, Liverpool School of
Tropical Medicine, Pembroke Place, Liverpool L3 5QA, Zimbabwe. 9Centre for
Sexual Health and HIV/AIDS Research (CeSHHAR), 9 Monmouth Road,
Avondale West Harare, Zimbabwe. 10Faculty of Public Health & Policy,
London School of Hygiene & Tropical Medicine, 15-17 Tavistock Place,
London WC1H 9SH, UK. 11Faculty of Infectious and Tropical Diseases, London
School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT,
UK.
Received: 23 May 2018 Accepted: 3 July 2018
References
1. UNAIDS, 2016. Prevention gap report http://www.unaids.org/en/resources/
documents/2016/prevention-gap
2. UNAIDS, 2016. All in to end the adolescent AIDS epidemic: A progress
report. http://www.unaids.org/sites/default/files/media_asset/
ALLIN2016ProgressReport_en.pdf
3. United Nations, 2012. World Population Monitoring: Adolescents and Youth.
United Nations Department of Economic and Social Affairs, Population
Division.
4. Mavedzenge SN, Luecke E, Ross DA. Effective approaches for programming
to reduce adolescent vulnerability to HIV infection, HIV risk, and HIV-related
morbidity and mortality: a systematic review of systematic reviews. J Acquir
Immune Defic Syndr. 2014;66(Suppl 2):S154–69.
5. Bundy DAP, de Silva N, Horton S, Patton GC, Schultz L, Jamison DT. Disease
control priorities C, adolescent H, development authors G: investment in
child and adolescent health and development: key messages from disease
control priorities, 3rd edition. Lancet. 2018;391(10121):687–99.
6. Dehne KL, Dallabetta G, Wilson D, Garnett GP, Laga M, Benomar E, Fakoya
A, Baggaley RC, Nelson LJ, Kasedde S, et al. HIV prevention 2020: a
framework for delivery and a call for action. The lancet HIV.
2016;3(7):e323–32.
7. PEPFAR, BMGF, GirlEffect, Johnson&Johnson, ViiV Healthcrae, Gilead, 2016.
DREAMS Core Package of Interventions Summary. https://www.pepfar.gov/
documents/organization/269309.pdf
8. Hensen B, Hargreaves JR, Chiyaka T, Chabata S, Mushati P, Floyd S,
Birdthistle I, Busza J, Cowan F. Evaluating the impact of DREAMS on HIV
incidence among young women who sell sex: protocol for a non-
randomised study in Zimbabwe. BMC Public Health. 2018;18(1):203.
9. PEPFAR, 2015. DREAMS Country Fact Sheets. https://www.pepfar.gov/
partnerships/ppp/dreams/c69041.htm
10. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, Moore L,
O'Cathain A, Tinati T, Wight D, et al. Process evaluation of complex
interventions: Medical Research Council guidance. BMJ. 2015;350:h1258.
11. Garnett GP, Hallett TB, Takaruza A, Hargreaves J, Rhead R, Warren M,
Nyamukapa C, Gregson S. Providing a conceptual framework for HIV
prevention cascades and assessing feasibility of empirical measurement
with data from East Zimbabwe: a case study. The lancet HIV. 2016;3(7):
e297–306.
12. Hargreaves JR, Delany-Moretlwe S, Hallett TB, Johnson S, Kapiga S,
Bhattacharjee P, Dallabetta G, Garnett GP. The HIV prevention cascade:
integrating theories of epidemiological, behavioural, and social science into
programme design and monitoring. The Lancet HIV. 2016;3(7):e318–22.
13. Odhiambo FO, Laserson KF, Sewe M, Hamel MJ, Feikin DR, Adazu K,
Ogwang S, Obor D, Amek N, Bayoh N, et al. Profile: the KEMRI/CDC health
and demographic surveillance system–western Kenya. Int J Epidemiol. 2012;
41(4):977–87.
14. Beguy D, Elung'ata P, Mberu B, Oduor C, Wamukoya M, Nganyi B, Ezeh A.
Health & Demographic Surveillance System Profile: the Nairobi urban health
and demographic surveillance system (NUHDSS). Int J Epidemiol. 2015;44(2):
462–71.
15. De Meyer S, Kagesten A, Mmari K, McEachran J, Chilet-Rosell E, Kabiru CW,
Maina B, Jerves EM, Currie C, Michielsen K. "Boys should have the courage
to ask a girl out": gender norms in early adolescent romantic relationships.
J Adolesc Health. 2017;61(4S):S42–7.
16. Mtetwa S, Busza J, Chidiya S, Mungofa S, Cowan F. "You are wasting our
drugs": health service barriers to HIV treatment for sex workers in
Zimbabwe. BMC Public Health. 2013;13:698.
17. Habicht JP, Victora CG, Vaughan JP. Evaluation designs for adequacy,
plausibility and probability of public health programme performance and
impact. Int J Epidemiol. 1999;28(1):10–8.
Birdthistle et al. BMC Public Health  (2018) 18:912 Page 14 of 15
18. De Silva MJ, Breuer E, Lee L, Asher L, Chowdhary N, Lund C, Patel V. Theory
of change: a theory-driven approach to enhance the Medical Research
Council's framework for complex interventions. Trials. 2014;15:267.
19. Population Council, 2016. Building Girls' protective assets: a collection of
tools for program design.
20. Larmarange J, Mossong J, Barnighausen T, Newell ML. Participation
dynamics in population-based longitudinal HIV surveillance in rural South
Africa. PLoS One. 2015;10(4):e0123345.
21. Borgdorff MW, Kwaro D, Obor D, Otieno G, Kamire V, Odongo F, Owuor P,
Muthusi J, Mills LA, Joseph R, et al. HIV incidence in western Kenya during
scale-up of antiretroviral therapy and voluntary medical male circumcision:
a population-based cohort analysis. The lancet HIV. 2018;5(5):e241–9.
22. PEPFAR, 2017. Monitoring, Evaluation, and Reporting (MER2.0): Indicator
Reference Guide, Version 2.1. https://www.pepfar.gov/documents/
organization/263233.pdf
Birdthistle et al. BMC Public Health  (2018) 18:912 Page 15 of 15
